Private Equity Portfolio News: Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines
– Proceeds will support clinical development of lead pipeline candidates: ENV-101 for fibrotic lung diseases including idiopathic pulmonary fibrosis, and ENV-501, a next-generation HER3-targeted antibody-drug conjugate, for solid tumors –…